Our product

Discovery of a new target

Despite optimal management of MI patients, mortality and morbidity levels (particularly from heart failure) are still too high.
In addition, the World Health Organization predicts that these levels will rise as a result of the aging population and the current global diabetes epidemic.
Reperfusion diagram
The main challenge in improving the benefit of reopening an occluded artery (angioplasty reperfusion) arises from the adverse effects associated with the sudden return of oxygenated blood to the ischemic heart muscle (1). This stimulates the export of the DAXX protein from the nucleus (where it plays anti-apoptotic functions) to  the cytoplasm. DAXX binds the intracellular part of FAS (First Apoptosis Signal) receptor (2), triggering apoptosis that contributes to the so-called reperfusion injury (3).

Our therapeutic solution

 

The anti-apoptotic peptide Tat-DAXXp administered at the onset of artery reopening is internalized into cardiac cells (4). In the cytoplasm, APO-29 prevents FAS:DAXX interaction (5), thus inhibiting apoptosis-induced reperfusion injury (6). Unbound DAXX returns to the nucleus to play an anti-apoptotic role (7).

Reperfusion diagram